| abstract |
NEW INTERFERON ALFA STABLE GLYCOL POLYETHYLENE CONJUGATE, REPRESENTED BY A POSITIONAL ISEMER; The present invention relates to the field of the pharmaceutical industry and medicine, particularly to novel PEG-interferon derivatives and to the discovery of a novel, highly stable, functionally active interferon conjugate for interferon alfa activity with reduced immunogenicity. , with prolonged biological effects and improved pharmacokinetic parameters of the general formula: where: n - integral values of 227 to 10,000, so that the molecular weight of PEG is approximately 10,000 - 40,000 Da; m-integer <4> 4; IFN-natural or recombinant polypeptide exhibiting IFN-alpha activity. to drugs containing said conjugate of formula (I), pharmaceutical compositions containing PEG-IFN conjugate and therapeutically acceptable excipients suitable for the treatment of viral infections and cancer, as well as diseases associated with imodeficiency. The invention also relates to the use of conjugate in formula (I) in medicinal products which exhibit antiviral, antiproliferative and immunomodulatory activity, methods of prevention and / or treatment of diseases associated with primary or secondary imodeficiency. include administering a therapeutically effective amount of conjugate of formula (1), and to the container with such pharmaceutical composition. |